These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
745 related articles for article (PubMed ID: 28288656)
1. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656 [TBL] [Abstract][Full Text] [Related]
2. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568 [TBL] [Abstract][Full Text] [Related]
3. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related]
4. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. Hillerdal V; Ramachandran M; Leja J; Essand M BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073 [TBL] [Abstract][Full Text] [Related]
5. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
6. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
7. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy. Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655 [TBL] [Abstract][Full Text] [Related]
8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
9. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368 [TBL] [Abstract][Full Text] [Related]
10. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
14. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991 [TBL] [Abstract][Full Text] [Related]
15. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019 [TBL] [Abstract][Full Text] [Related]
16. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017 [TBL] [Abstract][Full Text] [Related]
17. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
18. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y Front Immunol; 2021; 12():724211. PubMed ID: 34675920 [TBL] [Abstract][Full Text] [Related]
19. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586 [TBL] [Abstract][Full Text] [Related]
20. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]